Summary:
- The FDA has canceled an upcoming advisory committee meeting to discuss the selection of influenza vaccine strains for the 2023-2024 flu season.
- The decision was made due to the ongoing COVID-19 pandemic and the need to focus resources on the development and distribution of COVID-19 vaccines.
- The FDA will still make the final decision on the flu vaccine strain selection for the upcoming season, but without the input of the advisory committee.